PL1651615T3 - Pirydazynylo-piperazyny oraz ich zastosowanie jako ligandów receptora histaminowego H3 - Google Patents

Pirydazynylo-piperazyny oraz ich zastosowanie jako ligandów receptora histaminowego H3

Info

Publication number
PL1651615T3
PL1651615T3 PL04738980T PL04738980T PL1651615T3 PL 1651615 T3 PL1651615 T3 PL 1651615T3 PL 04738980 T PL04738980 T PL 04738980T PL 04738980 T PL04738980 T PL 04738980T PL 1651615 T3 PL1651615 T3 PL 1651615T3
Authority
PL
Poland
Prior art keywords
histamine
compounds
receptor
piperazines
pyridazinyl
Prior art date
Application number
PL04738980T
Other languages
English (en)
Inventor
Rolf Hohlweg
Original Assignee
High Point Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34105630&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1651615(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by High Point Pharmaceuticals Llc filed Critical High Point Pharmaceuticals Llc
Publication of PL1651615T3 publication Critical patent/PL1651615T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20Nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL04738980T 2003-07-29 2004-07-06 Pirydazynylo-piperazyny oraz ich zastosowanie jako ligandów receptora histaminowego H3 PL1651615T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200301107 2003-07-29
US49269303P 2003-08-05 2003-08-05
PCT/DK2004/000483 WO2005009976A1 (en) 2003-07-29 2004-07-06 Pyridazinyl- piperazines and their use as histamine h3 receptor ligands
EP04738980A EP1651615B1 (en) 2003-07-29 2004-07-06 Pyridazinyl- piperazines and their use as histamine h3 receptor ligands

Publications (1)

Publication Number Publication Date
PL1651615T3 true PL1651615T3 (pl) 2010-08-31

Family

ID=34105630

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04738980T PL1651615T3 (pl) 2003-07-29 2004-07-06 Pirydazynylo-piperazyny oraz ich zastosowanie jako ligandów receptora histaminowego H3

Country Status (19)

Country Link
US (1) US7294626B2 (pl)
EP (1) EP1651615B1 (pl)
JP (1) JP4680903B2 (pl)
KR (1) KR20060054392A (pl)
CN (1) CN100584831C (pl)
AT (1) ATE461178T1 (pl)
AU (1) AU2004259263B2 (pl)
BR (1) BRPI0413048A (pl)
CA (1) CA2532236C (pl)
DE (1) DE602004026068D1 (pl)
DK (1) DK1651615T3 (pl)
ES (1) ES2342605T3 (pl)
IL (1) IL173161A0 (pl)
MX (1) MXPA06001053A (pl)
NO (1) NO20061003L (pl)
PL (1) PL1651615T3 (pl)
PT (1) PT1651615E (pl)
RU (1) RU2006101452A (pl)
WO (1) WO2005009976A1 (pl)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030176437A1 (en) 2001-08-31 2003-09-18 D.M. Watterson Anti-inflammatory and protein kinase inhibitor compositions and related methods for downregulation of detrimental cellular responses and inhibition of cell death
US20030236259A1 (en) * 2002-02-05 2003-12-25 Rolf Hohlweg Novel aryl- and heteroarylpiperazines
JP2007531753A (ja) 2004-03-31 2007-11-08 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 非イミダゾール系複素環式化合物
EP1595881A1 (en) * 2004-05-12 2005-11-16 Pfizer Limited Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands
EP1799668A1 (en) 2004-09-20 2007-06-27 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-coa desaturase
BRPI0515489A (pt) 2004-09-20 2008-07-29 Xenon Pharmaceuticals Inc derivados heterocìclicos e sua utilização como inibidores de estearoil-coa desaturase
US7919496B2 (en) 2004-09-20 2011-04-05 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-CoA desaturase enzymes
WO2006034446A2 (en) * 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Pyridine derivatives for inhibiting human stearoyl-coa-desaturase
JP5043668B2 (ja) 2004-09-20 2012-10-10 ゼノン・ファーマシューティカルズ・インコーポレイテッド 複素環誘導体および治療薬としてのそれらの使用
BRPI0515500A (pt) 2004-09-20 2008-07-29 Xenon Pharmaceuticals Inc derivados piridazina para inibição de estearoil-coa-desaturase
AU2005329423A1 (en) 2004-09-20 2006-09-28 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
AR051092A1 (es) 2004-09-20 2006-12-20 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de la estearoil-coa
EP2592075B1 (en) 2004-11-02 2015-04-29 Northwestern University Pyridazine compounds for the treatment of inflammatory diseases
CA2589102C (en) 2004-11-02 2013-08-13 Northwestern University Pyridazine compounds and methods for using the compounds to treat inflammatory diseases
CN101208089A (zh) 2005-06-03 2008-06-25 泽农医药公司 氨基噻唑衍生物作为人硬酯酰-CoA去饱和酶抑制剂
US8501739B2 (en) 2005-07-04 2013-08-06 High Point Pharmaceuticals, Llc Medicaments
GB0517184D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
JO2769B1 (en) 2005-10-26 2014-03-15 جانسين فارماسوتيكا ان. في Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor
US8158673B2 (en) * 2005-10-27 2012-04-17 Pfizer Inc. Histamine-3 receptor antagonists
US20090325973A1 (en) 2006-04-28 2009-12-31 Watterson D Martin Formulations containing pyridazine compounds
EP2015750A2 (en) 2006-04-28 2009-01-21 Northwestern University Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
JP2009537596A (ja) 2006-05-23 2009-10-29 ハイ ポイント ファーマシューティカルズ,リミティド ライアビリティ カンパニー 6−(4−シクロプロピルピペリジン−1−イル)−2’−メチル−[3,4’]−ビピリジン及びその医薬としての使用
KR20090040259A (ko) 2006-05-29 2009-04-23 하이 포인트 파마슈티칼스, 엘엘씨 3-(1,3-벤조디옥솔-5-일)-6-(4-시클로프로필피페라진-1-일)-피리다진, 그것의 염과 용매화합물 및 그것의 히스타민 h3 수용체 안타고니스트로서의 용도
AU2007256931B2 (en) 2006-05-30 2013-01-24 Janssen Pharmaceutica N.V. Substituted pyridyl amide compounds as modulators of the histamine H3 receptor
AU2007260836B2 (en) 2006-06-23 2012-11-15 Abbvie Bahamas Ltd. Cyclopropyl amine derivatives as histamin H3 receptor modulators
US9108948B2 (en) 2006-06-23 2015-08-18 Abbvie Inc. Cyclopropyl amine derivatives
JO2642B1 (en) 2006-12-08 2012-06-17 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
JO2849B1 (en) 2007-02-13 2015-03-15 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
MX2009011415A (es) 2007-04-23 2009-11-05 Janssen Pharmaceutica Nv Derivados de 4-alcoxipiridazina como antagonistas del receptor de dopamina 2 de rapida disociacion.
CA2682671C (en) 2007-04-23 2015-11-17 Janssen Pharmaceutica N.V. Thia(dia)zoles as fast dissociating dopamine 2 receptor antagonists
CA2687931C (en) 2007-05-31 2016-05-24 Boehringer Ingelheim International Gmbh Ccr2 receptor antagonists and uses thereof
EP2164519A2 (en) * 2007-06-08 2010-03-24 Ascendis Pharma AS Long-acting polymeric prodrugs of exendin
EP2014656A3 (en) 2007-06-11 2011-08-24 High Point Pharmaceuticals, LLC New heteocyclic h3 antagonists
KR101546712B1 (ko) 2007-11-20 2015-08-24 얀센 파마슈티카 엔.브이. 히스타민 h3 수용체의 조절제로서 사이클로알킬옥시- 및 헤테로사이클로알킬옥시피리딘 화합물
JP5417439B2 (ja) 2008-07-03 2014-02-12 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 5−ht6受容体アンタゴニストとしての置換された6−(1−ピペラジニル)−ピリダジン類
CN102171189B (zh) 2008-07-31 2013-11-20 詹森药业有限公司 作为快速解离多巴胺2受体拮抗剂的哌嗪-1-基-三氟甲基取代的吡啶
EA020548B1 (ru) 2008-12-19 2014-12-30 Бёрингер Ингельхайм Интернациональ Гмбх Циклические пиримидин-4-карбоксамиды в качестве антагонистов рецептора ccr2, предназначенные для лечения воспаления, астмы и хозл
US9186353B2 (en) 2009-04-27 2015-11-17 Abbvie Inc. Treatment of osteoarthritis pain
NZ599770A (en) 2009-12-17 2014-06-27 Boehringer Ingelheim Int New ccr2 receptor antagonists and uses thereof
WO2011141474A1 (en) 2010-05-12 2011-11-17 Boehringer Ingelheim International Gmbh Novel ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
WO2011141477A1 (en) 2010-05-12 2011-11-17 Boehringer Ingelheim International Gmbh New ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
US8841313B2 (en) 2010-05-17 2014-09-23 Boehringer Ingelheim International Gmbh CCR2 antagonists and uses thereof
WO2011147772A1 (en) * 2010-05-25 2011-12-01 Boehringer Ingelheim International Gmbh Ccr2 receptor antagonists
US8962656B2 (en) 2010-06-01 2015-02-24 Boehringer Ingelheim International Gmbh CCR2 antagonists
WO2012037258A1 (en) 2010-09-16 2012-03-22 Abbott Laboratories Processes for preparing 1,2-substituted cyclopropyl derivatives
JP5786258B2 (ja) 2011-07-15 2015-09-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規かつ選択的なccr2拮抗薬
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
FR2999427B1 (fr) * 2012-12-17 2015-01-30 Metabolys Composition et kit comprenant des derives de piperazine et de la metformine, leur utilisation dans le traitement du diabete
BR112017028492B1 (pt) 2015-07-02 2023-12-26 Centrexion Therapeutics Corporation Citrato de (4-((3r,4r)-3-metoxitetra-hidro-piran-4- ilamino)piperidin-1-il) (5- metil-6-(((2r, 6s)-6-(p-tolil) tetra-hidro-2h-piran-2-il)metilamino)pirimidin-4-il) metanona, seu uso e seu método de preparação, e composição farmacêutica

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4144346A (en) 1977-01-31 1979-03-13 Janssen Pharmaceutica N.V. Novel 1-(1,3-dioxolan-2-ylmethyl)-1H-imidazoles
FR2573075B1 (fr) 1984-09-14 1987-03-20 Innothera Lab Sa Nouvelles (pyridyl-2)-1 piperazines, leur procede de preparation et leur application en therapeutique
IL135574A0 (en) 1997-10-27 2001-05-20 Agouron Pharma Substituted 4-amino-thiazol-2-yl compounds as cdk inhibitors
AU2935200A (en) 1999-04-30 2000-11-17 Pfizer Products Inc. Compounds for the treatment of obesity
WO2001066534A2 (en) 2000-03-09 2001-09-13 Abbott Laboratories Cyclic and bicyclic diamino histamine-3 receptor antagonists
AU2001251083A1 (en) 2000-03-31 2001-10-15 Ortho-Mcneil Pharmaceutical, Inc. Method for using 2-aryloxyalkylaminobenzoxazoles and 2-aryloxyalkylaminobenzothiazoles as h3 antagonists
US6316475B1 (en) 2000-11-17 2001-11-13 Abbott Laboratories Aminoalkoxybiphenylcarboxamides as histamine-3 receptor ligands and their therapeutic applications
MXPA04007612A (es) * 2002-02-05 2004-11-10 Novo Nordisk As Aril- y heteroarilpiperazinas novedosas.

Also Published As

Publication number Publication date
ES2342605T3 (es) 2010-07-09
ATE461178T1 (de) 2010-04-15
IL173161A0 (en) 2006-06-11
CN100584831C (zh) 2010-01-27
AU2004259263B2 (en) 2010-12-16
JP2007500135A (ja) 2007-01-11
BRPI0413048A (pt) 2006-10-17
CA2532236C (en) 2011-08-23
NO20061003L (no) 2006-04-26
EP1651615A1 (en) 2006-05-03
DK1651615T3 (da) 2010-05-25
RU2006101452A (ru) 2006-06-27
PT1651615E (pt) 2010-04-29
EP1651615B1 (en) 2010-03-17
MXPA06001053A (es) 2006-04-11
DE602004026068D1 (de) 2010-04-29
US7294626B2 (en) 2007-11-13
KR20060054392A (ko) 2006-05-22
AU2004259263A1 (en) 2005-02-03
CN1829699A (zh) 2006-09-06
JP4680903B2 (ja) 2011-05-11
CA2532236A1 (en) 2005-02-03
WO2005009976A1 (en) 2005-02-03
US20060173012A1 (en) 2006-08-03

Similar Documents

Publication Publication Date Title
IL173161A0 (en) Pyridazinyl-piperazines and their use as histamine h3 receptor ligands
DE60237528D1 (de) Neue aminoazetidin-, aminopyrrolidin- und aminopiperidinderivative
WO2003066604A3 (en) Novel aryl- and heteroarylpiperazines
MY138836A (en) Quinoline derivatives and their use as 5-ht6 receptor ligands
SI1735278T1 (sl) Agenti histamin h receptorja priprava in terapevtska uporaba
MY140693A (en) [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
EA200601897A1 (ru) Производные тетрагидронафтиридина, пригодные в качестве лигандов рецептора н3 гистамина
IL162834A0 (en) Amides of aminoalkyl-substituted azetidines, pyrrolidines, piperidines and azepanes
NO20070347L (no) Modulatorer av alfa7 nikotinske acetylkolinreseptorer og terapeutiske anvendelser
TW200611695A (en) Pyrrolopyridine derivatives
TW200504034A (en) Therapeutic agents
DK1725536T3 (da) Imidazolin-derivater med CB1-antagonistisk aktivitet
GB0222495D0 (en) Compounds
TW200635903A (en) Therapeutic agents
WO2006067428A3 (en) 1, 2-diphenyl-imidazole derivatives and their use as cb1 receptor ligands
WO2005037798A3 (en) Amide or thiomide derivatives and their use in the treatment of pain
TW200745122A (en) New compounds I
MX2007007027A (es) Derivados piperazinilpiridina como agentes anti-obesidad.
TW200726763A (en) Novel compound
EP1398029A8 (en) NR3B1 nuclear receptor binding 3-substituted pyrazole derivatives
TW200514781A (en) Novel compounds
MY146802A (en) Novel drugs for treating respiratory diseases
GB0320320D0 (en) Novel compounds
AU2003229535A1 (en) Substituted hexahydropyrrolo(1,2-a)pyrazines, octahydropyrido(1,2-a)pyrazines and decahydropyrazino(1,2-a)azepines
EP1608352A4 (en) POLYAMINE COMPOUNDS FOR THE TREATMENT OF CHEMOKINE-RECEPTOR INDUCED DISEASES